Nimbus Therapeutics Raises $210 Million for Small Molecule Drug Discovery
Boston-based Nimbus Therapeutics, a biotech firm, has announced that it has secured $210 million in venture capital funding. This investment will support the company's efforts to advance its portfolio of drugs targeting various disorders, including cancer.
09/09/2023, 11:32PM
Related Articles (6)
BioPharma Dive
Fresh off $4B deal, Nimbus gears up for ‘third chapter’ with new fundraise
The Boston biotech has sold two experimental drugs — a liver disease medicine and a TYK2 inhibitor — to Gilead and Takeda respectively.
BostonGlobe.com
Nimbus Therapeutics raises $210 million in fundraising round
The Boston-based biotech will work on new ‘small molecule’ drugs to combat cancer and other ailments.
